I’m pleased to share three papers in Cancer Discovery- Elizabeth McKenna

I’m pleased to share three papers in #CancerDiscovery that were published simultaneously with posters/presentations at #ASCO23:

From the Developmental Therapeutics Poster Discussion Session: “SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy” by Alexander Drilon, S. Michael Rothenberg, and colleagues  along with an accompanying Spotlight, “Patient Centric Approaches for Phase I Combination Trials Come on Stage” by Alberto Hernando Calvo and Elena Garralda Cabanas  From the Sarcoma Poster Session: “The MDM2–p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study” by Mrinal Gounder and colleagues.
And from a Clinical Science Symposium: “RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations” by Vivek Subbiah, MD, Jessica Casaletto and colleagues.

Source: Elizabeth McKenna/Linkedin